INTRODUCTION
Hypoxic ischaemic encephalopathy (HIE) is one of the most serious perinatal complications, and remains associated with a high risk of death or long-term neurodisability. Despite advances in obstetric care, moderate-to-severe HIE affects 1.5-3 per 1000 term live births in developed countries. [1, 2] There is now compelling evidence that mild hypothermia induced within 6 hours after resuscitation can improve long-term survival without disability. [3] However, many infants still die or survive with disability, and recent data suggest that longer or deeper cooling did not reduce death at hospital discharge. [4] Thus, it is important to investigate whether other factors may help to further optimize care.
Glucose is the primary substrate for energy metabolism in the newborn brain, and deranged metabolism may contribute to neuronal injury. [5, 6] At birth, the continuous transplacental infusion of glucose ends; normal postnatal glucose homeostasis then depends on hepatic glycogen reserves, hormonal regulation, and external provision of enteral or parenteral substrate.
Hypoglycaemia and hyperglycaemia occur frequently in infants with HIE, likely due to the profound metabolic and hormonal disturbances. [7] [8] [9] Their effect on long-term outcome is unclear. Although one study found that early hypoglycaemia was a risk factor for short-term perinatal brain injury in newborns with HIE, [9] others did not find a relationship between early hypoglycaemia and adverse neurodevelopmental outcome at 24 months age after adjusting for HIE severity. [7] Two retrospective studies reported conflicting results on the association 4 between early hyperglycaemia and unfavourable outcome in infants with HIE. [7, 10] Thus, there is no conclusive evidence that deranged glucose metabolism in infants with HIE is independently associated with unfavourable long-term neurologic outcome.
Animal studies support the potential for neuronal injury from deranged glucose homeostasis in the setting of asphyxia. Induced hypoglycaemia decreased the cerebrovascular response to hypoxia, increased cerebral superoxide production and aspartate levels in the brain extracellular space, and promoted neuronal necrosis. [11] [12] [13] [14] Hyperglycaemia before acute hypoxia-ischaemia or ischaemia markedly increased brain injury in animal models. [15] [16] [17] We therefore examined the hypothesis that early transient or recurrent hypoglycaemia (≤40 mg/dL, ≤2.2 mmol/L) [8] and hyperglycaemia (>150 mg/dL, 8.3 mmol/L) [7] in infants with moderate-to-severe HIE would be independently associated with death or severe neurodevelopmental disability (primary unfavourable outcome) in a post-hoc analysis from the CoolCap Study. [18] 5
METHODS

Subjects
The CoolCap Study was a multicentre randomised controlled study of selective head cooling and mild systemic hypothermia for the treatment of perinatal moderate-to-severe HIE in 234 infants at ≥36 weeks' gestation enrolled between 1999 to 2002. [18] This study was performed in 25 perinatal centres using a trial design registered with the US Food and Drug Administration under the Investigational Device Exemption/Premarket Approval program. The institutional review board at each centre approved the protocol, and written informed consent was obtained from parents before randomization. Study subjects were randomised to head cooling for 72 hours starting within 6 hours of birth, with rectal temperature maintained at 34.5±0.5C, followed by rewarming over 4 hours, or standard care at 37.0±0.5C. The primary unfavourable study outcome was death or severe disability (i.e., Gross motor function classification system level 3- 
RESULTS
Study demographic data stratified by 18-month outcome are shown in table 1. Infants with an unfavourable outcome were generally larger, less likely to have been cooled, had more severe vs. moderate HIE, had lower 5-minute Apgar scores, and were more acidotic. Incidentally, only 4 study infants had septicaemia. Therefore, meaningful statistical associations between septicaemia and glucose derangements and outcome could not be established. Table 1 Baseline characteristics of infants from the CoolCap Study *Delivery complications include prolapsed cord, true knot in the cord, umbilical cord tear, shoulder dystocia, placental abruption, feto-maternal bleeding, ruptured uterus, antepartum haemorrhage, traumatic instrument delivery, head entrapment, and others.
Early postnatal glucose profile
The time period after randomisation that was most informative for predicting an unfavourable outcome was during the first 12 hours. At the time of randomisation, of infants with recorded plasma glucose levels, 7% (15/205) were hypoglycaemic and 34% (70/205) were hyperglycaemic. During the first 12 hours, 13% (27/214) of infants had at least one episode of 
DISCUSSION
This study reports systematically collected and analysed evidence that early hypoglycaemia, hyperglycaemia, and indeed, any glucose derangement during the early postnatal period, in infants with moderate-to-severe HIE are independently associated with an unfavourable outcome at 18 months. It is not possible to determine from this exploratory analysis whether this association with deranged glucose metabolism is causal. Hypoglycaemia reflects at least in part depletion of hepatic glycogen reserves during severe asphyxia, and hepatic injury. [20] Similarly, hyperglycaemia may be a proxy for severity of brain injury, as severely damaged tissues show reduced net metabolism, [21] or due to prolonged elevation of stress hormones after asphyxia. [22] Consistent with the present study, neonatal hyperglycaemia is common in preterm and sick infants. [23] The specific mechanisms are likely multifactorial, related to impaired insulin response, excessive hepatic glucose production, sepsis, and stress-induced increase in counter-regulatory hormones. [24, 25] Neonatal hypoglycaemia has been investigated for its association with unfavourable neurodevelopmental and academic outcome in term and preterm infants. [26] [27] [28] Although the definition of neonatal hypoglycaemia has been highly controversial, the American Academy of Pediatrics currently recommends early identification of the at-risk infant and institution of prophylactic measures to prevent neonatal hypoglycemia. [29] However, only a few studies have examined the influence of early hypoglycaemia in infants with HIE on long-term neurodevelopmental outcome. [7] [8] [9] 30 ] One study of 60 infants with HIE showed a significant association between hypoglycaemia and HIE severity, but did not evaluate longer-term outcomes. [9] In another study of 185 term infants with fetal acidemia, investigators observed that hypoglycaemia was associated with early abnormal neurologic outcome (i.e., severe HIE
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and death, moderate-to-severe HIE, and seizures). However, this study did not evaluate outcome after hospital discharge. [8] In another study, although early hypoglycaemia was associated with adverse outcome at 24 months in 52 term infants with HIE in univariate analysis, hypoglycaemia was not a significant predictor after adjustment for severity of HIE. [7] None of the infants included in the above studies received therapeutic hypothermia. [7] [8] [9] More recently, in a prospective cohort study of 94 term infants at risk for neonatal encephalopathy, of whom 12%
were treated with hypothermia, investigators reported that hypoglycaemia was associated with worse motor and cognitive outcome at 1 year.
[30]
There are very limited data describing hyperglycaemia in neonates outside of sick extremely premature infants or due to iatrogenic causes, and its relationship with outcome is not clearly understood. [23] A retrospective analysis of 52 term infants with HIE found that hyperglycaemia occurred frequently but was not associated with an unfavourable outcome. [7] Conversely, in a smaller retrospective study, early hyperglycaemia (in univariate analysis only) in infants with HIE was associated with long-term gross motor deficits. [10] We previously reported that mild hypothermia was associated with an early increase in mean plasma glucose levels. [18] The present study demonstrates that hypoglycaemia as well as hyperglycaemia during the first 12 hours were associated with an unfavourable outcome at 18 months age, independent of severity of HIE and cooling therapy. Hyperglycaemia during hypoxia-ischaemia or ischaemia increases subsequent brain injury in piglets, fetal sheep, and adult rodents. [15] [16] [17] In fetal sheep, hyperglycaemia during asphyxia reduces cerebral oxygen consumption and increases acidosis. [32] In contrast, post-insult treatment has had variable results. Some studies, in neonatal rodents, piglets, and fetal sheep have suggested no effect. [16, 33, 34] In contrast, in newborn piglets, hyperglycaemia impaired recovery of brain cell membrane function and energy metabolism. [35] Further, hyperglycaemia following maternal dexamethasone treatment after asphyxia in fetal sheep was associated with increased brain injury. [36] It may be that these contrasting results reflect more adverse effects of greater durations of hyperglycaemia, or a deleterious effect of the combination of high levels of glucocorticoids with hyperglycaemia. Finally, it is interesting to note that although glucose infusion after asphyxial cardiac arrest per se did not increase injury in adult rats, a combined glucose and insulin infusion markedly reduced histological brain injury. [37] 18 F-fluorodeoxyglucose positron emission tomography imaging in infants with HIE has found deranged glucose metabolism in affected brain areas. [38] Total and regional cerebral glucose metabolic rates measured during the subacute period after perinatal asphyxia in term infants was inversely correlated with HIE severity and short-term outcome.
[39] Magnetic resonance imaging on day 3 in infants with HIE and hypoglycaemia suggests that hypoglycaemic brain injury was superimposed on patterns of hypoxic ischaemic brain injury. [40] Several limitations of the present study should be taken into consideration. The analysis was post hoc, and so it is important that the findings are confirmed in prospective studies. We do not
have glucose values between the pre-defined time points or continuous values and so may have 14 underestimated the true incidence and duration of hypoglycaemia and hyperglycaemia. However, the study is strengthened by the regular and systematic determination of glucose levels at discrete time points that were not dependent on clinical decisions as in other retrospective studies.
Glucose infusion rates from parenteral nutrition and intravenous fluids were not standardized across subjects, and this information was not available for the present exploratory analysis.
Further, there was no information regarding treatment thresholds or interventions used, as this was not pre-specified by the original study, whether interventions were provided, or how interventions to achieve normoglycaemia influenced outcome. Thus, the trend of glucose levels towards normoglycaemia over time could represent a response to treatment or more likely, the natural history of improving glucose homeostasis in infants with moderate-to-severe HIE. We also do not have information on the source (arterial, venous, or capillary) of blood samples, and whether different sources of glucose levels could affect interpretation. Future prospective studies are needed to further investigate these associations.
CONCLUSIONS
Deranged glucose homeostasis was common during the first 12 hours after randomisation in infants with moderate-to-severe HIE. Both hypoglycaemia and hyperglycaemia were associated with unfavourable outcome at 18 months of age, independent of HIE severity and hypothermia treatment. Future studies are needed to investigate whether early deranged glucose metabolism in infants with HIE is a biomarker for neuronal injury, has prognostic significance, and aggravates further brain injury.
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